Federal Tipoffs Involving Maryland Newsletter for Wednesday November 20, 2024 ( 3 items ) |
Agency for Healthcare Research: 'Overview of Methicillin-Resistant Staphylococcus Aureus (MRSA)-Related Adult Inpatient Stays, 2016-2021'
ROCKVILLE, Maryland, Nov. 19 (TNSres) -- The Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project issued the following statistical brief in November 2024 entitled "Overview of Methicillin-Resistant Staphylococcus aureus (MRSA)-Related Adult Inpatient Stays, 2016-2021":
Here are excerpts:
* * *
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is resistant to almost all antibiotics in the beta-lactam class, including penicillin, methicillin, amo
more
New Path for a Gene Therapy Trial at NIH for a Rare Metabolic Disease
BETHESDA, Maryland, Nov. 20 (TNSres) -- The U.S. Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences issued the following news:
When Selecta Biosciences decided not to pursue a clinical trial on a promising gene therapy for a rare metabolic disease in 2023, it could have been the end of the research, despite years of work. Instead, NCATS and NIH's National Human Genome Research Institute (NHGRI) signed an agreement to collab
more
NIH National Center for Advancing Translational Sciences: Spectradyne - SBIR Funding Spurs Advances in Nanoparticle Technology
BETHESDA, Maryland, Nov. 20 (TNSres) -- The U.S. Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences issued the following news:
* * *
Analyzers speed diagnostic and treatment development
* * *
One of the biggest achievements in modern medicine involves some of the smallest known substances. Much of today's biological research and drug development involves tiny particles, each smaller than one millionth of a millimeter - t
more
|
Sign up to Receive this newsletter every day via email.